Table 1.
Characteristics of the included studies.
| Reference | Year | Disease | Sample size (E/C) | Sex (M/F) | Age(years) (E/C) | Interventions | Follow-up time | Outcome measures | Criteria for efficacy | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| E | C | E | C | ||||||||
| Dang et al. [15] | 2014 | GC (advanced) | 100(50/50) | Unknown | 61.06 ± 4.21/60.21 ± 4.62 | Rg3 +C | DDP + placebo | 8 months | ①②④⑤ | WHO | |
| Liu et al. [16] | 2017 | GC (IIIA: 15, IIIB: 52, IIIC: 22) | 89(52/37) | 29/23 | 20/17 | 45.1 ± 8.5/44.8 ± 9.3 | Rg3 +C | FOLFOX4 | 6 months | ①②⑤ | RECIST |
| Wei et al. [17] | 2015 | GC (III-IV) | 200(100/100) | 68/32 | 70/30 | 18–75(48.5 ± 6.7)/19–74(46.5 ± 5.7) | Rg3 +C | Tegafur + DDP | 5 years | ①②⑤ | RECIST |
| Zhou et al. [18] | 2013 | GC (advanced) | 80(40/40) | Unknown | 44–73(61)/43–72 (60)(median age) | Rg3 +C | PTX | 4 years | ①③⑤ | WHO | |
| Bian et al. [19] | 2014 | CRC (advanced) | 61(30/31) | 18/12 | 17/14 | 54.6 ± 9.6/57.1 ± 7.4 | Rg3 +C | XELOX | 2 years | ⑤ | RECIST |
| Gai et al. [20] | 2010 | CRC (advanced) | 49(25/24) | 28/21 | 35–75 | Rg3 +C | XELOX | 9 weeks | ①②④⑤ | WHO | |
| Liu et al. [21] | 2015 | CRC III (77%), IV (23%) | 113(63/50) | 53/60 | 18–80 (median age 55) | Rg3 +C | Fluorouracil + placebo | 14 months | ①②④⑤ | WHO | |
| Lou [22] | 2010 | CRC (II-III) | 94(47/47) | Unknown | 41–75 | Rg3 +C | FOLFOX6 | 2 months | ⑤ | RECIST | |
| Zeng et al. [23] | 2009 | CRC (IV) | 67(35/32) | 25/10 | 22/11 | 51–69 | Rg3 +C | FOLFOX4 | 2 months | ①②④⑤ | WHO |
| Huang et al. [24] | 2009 | EC (IV) | 60(30/30) | 17/13 | 18/12 | 45–75(54)/42–74 (52)(median age) | Rg3 +C | GP(GEM + DDP) | 1 year | ①②③④⑤ | WHO |
| Wang [25] | 2010 | EC (advanced) | 70(35/35) | 46/24 | 32–78 (median age 56) | Rg3 +C | NP(NVB + DDP) | 6 weeks | ①②④⑤ | WHO | |
| Zhou [26] | 2015 | EC (T3-T4a) | 207(99/108) | 65/34 | 70/38 | 48–76(61.6 ± 7.6)/50–79(63.5 ± 8.4) (average age) | Rg3 +C | TP(PTX + DDP) | 3 years | ①②③⑤ | WHO |
| Liu et al. [27] | 2015 | LC (advanced) | 64(32/32) | 18/14 | 17/15 | 52.13 ± 10.25/53.27 ± 11.59 | Rg3 +C | TACE + lipiodol + pirarubicin | 3 months | ①②⑤ | GPCRNCM |
| Ouyang et al. [28] | 2009 | LC (II: 9, III: 39, IV: 13) | 61(30/31) | 25/5 | 23/8 | 21–72 (median age 50) | Rg3 +C | TACE + lipiodol | 2 years | ①②③④⑤ | GPCRNCM |
| Zhao et al. [29] | 2009 | LC (advanced) | 40(20/20) | 14/6 | 16/4 | 59.5 ± 11.6/62.3 ± 10.8 | Rg3 +C | TACE + GP + ML | 2 years | ①②③④⑤ | GPCRNCM |
| Chen et al. [30] | 2012 | LC (advanced) | 60(30/30) | Unknown | Unknown | Rg3 +C | TACE + Fluorouracil + DDP + ML | 3 years | ②③④⑤ | WHO | |
| Wang et al. [31] | 2014 | LC (advanced) | 48(24/24) | 29/19 | 52.13 ± 3.65 | Rg3 +C | TACE + mitomycin + adriamycin+ | 6 months | ①②⑤ | Unknown | |
| Li [32] | 2018 | PC (III: 59, IV: 9) | 68(34/34) | 21/13 | 20/14 | 52.2 ± 3.8/52.3 ± 3.9 | Rg3 +C | GEM | 4 months | ⑤ | Unknown |
Note. E: experimental group; C: control group; Rg3: Rg3 20 mg po.Bid; PTX: paclitaxel; DDP: cisplatin; XELOX: oxaliplatin + capecitabine; FOLFOX4/FOLFOX6: oxaliplatin + calcium folinate + fluorouracil; GP (GEM + DDP): gemcitabine + cisplatin; TP (PTX + DDP): paclitaxel + cisplatin; NP (NVB + DDP): vinorelbine + cisplatin; TACE: transcatheter arterial chemoembolization; ML: mitomycin + lipiodol; WHO: World Health Organization; RECIST: the response evaluation criteria in solid tumors; GPCRNCM: Guiding Principles for Clinical Research of New Chinese Medicines; ① ORR; ② DCR; ③ SR; ④ KPS; ⑤ side effects.